Navigation Links
Mardil Inc. Appoints Medical Device Veteran Daniel A. Pelak to Its Board of Directors
Date:2/19/2009

RESEARCH TRIANGLE PARK, N.C., Feb. 19 /PRNewswire/ -- Mardil Inc., a cardiac medical device company with novel technology for treating mitral valve regurgitation, today announced the appointment of Daniel A. Pelak to its board of directors.

Mr. Pelak's significant experience in the field of cardiac medical devices will serve as a guiding force for Mardil, a company that has rapidly advanced its unique device from the development stage to human trials within a span of 2 years, according to Gopal Muppirala, CEO and co-founder of Mardil.

"Dan has a long history as a senior executive in the medical device industry, garnering multiple successes in growing young companies and managing corporate operating divisions," said Jai Ramon, M.D., Mardil co-founder and professor of surgery and director of adult cardiac surgery and cardiothoracic surgical research at the University of Chicago. "He has a wealth of experience commercializing cardiac devices, and we look forward to adding someone with Dan's background to our board."

The Mardil device, called BACE (basal annuloplasty of the cardia externally), began first-in-human testing in India last month, and clinical trials will expand internationally in the third quarter of 2009. The BACE device serves as a tension band that encircles the heart and supports the exterior heart muscle. Its gentle pressure enables the leaflets of the mitral valve to open and close properly and thus prevents the backflow of blood into the left ventricle, a condition called mitral regurgitation. The device is designed to be less invasive, less costly, and to reduce side effects and mortality rates associated with current mitral valve repair and replacement techniques.

"The BACE device is truly a breakthrough technology that has the potential to change the way we treat heart valve disease," Pelak said. "I am excited to be affiliated with a company that has successfully developed a truly novel alternative to invasive valvular replacement, and I look forward to contributing my skills toward advancing this therapy."

Currently Mr. Pelak is senior advisor to the private equity firm Welsh, Carson, Anderson and Stowe. Previously he served as the CEO of InnerPulse Inc. and as the CEO of Closure Medical Corp. until its acquisition by Johnson & Johnson in 2005. Pelak began his career at Medtronic Inc., where he advanced through multiple management positions over a 20-year period. His executive positions at Medtronic included vice president of cardiovascular marketing as well as vice president and general manager of three operating divisions: Nortech, Cardiac Surgery Technology, and Perfusion Systems.

ABOUT MARDIL INC.

Mardil Inc. is a medical device company whose mission is to design, develop and market new and innovative patented technologies in the cardiac medical device field. Each device will fulfill an unmet need in cardiovascular medical procedures by improving upon existing technology or by designing new technology that more effectively treats cardiovascular conditions. The company's first product is a minimally invasive device that treats functional mitral valve regurgitation. The device is currently undergoing human trials.


'/>"/>
SOURCE Mardil Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Consorta Board Appoints Darrel Weatherford President and Chief Executive Officer
2. IMIA Interpreter Association Appoints Canada Representative
3. Novo Nordisk Appoints Andy Ajello as Vice President for National Diabetes Sales, Managed Care and Government Accounts
4. Hillenbrand Board of Directors Appoints Joe Loughrey as New Director
5. Gold Partners Appoints Larry Bell, M.D. President, Regulatory, Quality, Safety and Risk Management Services
6. USHIFU Appoints Mark Schoenberg, M.D. Chief Medical Officer
7. Physiotherapy Associates Appoints Daniel J. Connors Chief Executive Officer
8. WorldHeart Appoints New President and CEO
9. WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board
10. ORBIS International Appoints New President
11. Vigilan Appoints Robin Hand to VP of Customer Support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... CO (PRWEB) , ... September 21, 2017 , ... ... Interview of the Month, Lewis and Clark College Emeritus Professor of Education Gregory ... Faith Boninger, co-author of Asleep at the Switch: Schoolhouse Commercialism, Privacy, and ...
(Date:9/20/2017)... ... September 20, 2017 , ... On ... Best Places to Work in the Research Triangle for 2017. , Winners were ... company had to meet a threshold in employee participation--a percentage that varies based ...
(Date:9/20/2017)... ... September 20, 2017 , ... Mirror Mirror Beauty ... , Look Awesome This Autumn with CoolSculpting®. Scheduled for Thursday, September 28th, the ... , Mirror Mirror Beauty Boutique is Houston’s largest CoolSculpting provider, holding ...
(Date:9/20/2017)... ... September 20, 2017 , ... Compliancy Group is proud ... The Guard®, has helped another long-time client pass their Department of Health and ... the law. , Thanks to the help of the Compliancy Group's Audit Response ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... Five consumer ... innovation and market impact in 27 different categories. Nopavera Plus was named ... category will be announced at SupplySide West 2017 during presentations at SupplySide Central on ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... STOCKHOLM , Sept. 7, 2017 NuvoAir ... Air Smart Spirometer, announced today a partnership with Novartis Pharma ... partnership solidifies NuvoAir,s position as the leading mobile spirometry platform ... respiratory patients. ... spirometry test ...
(Date:9/6/2017)... , Sept. 6, 2017  Robert G. Szewc, ... Pinnacle Professional Member in recognition of his contributions to ... serves as a Nephrologist at the practice of Kidney ... medicine, kidney care and hypertension solutions. He has worked ... years of career experience, as well as expertise in ...
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
Breaking Medicine Technology: